Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.amepre.2021.01.001

http://scihub22266oqcxt.onion/10.1016/j.amepre.2021.01.001
suck pdf from google scholar
33632650!7817395!33632650
unlimited free pdf from europmc33632650    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33632650      Am+J+Prev+Med 2021 ; 60 (5): 605-613
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine #MMPMID33632650
  • Bartsch SM; O'Shea KJ; Wedlock PT; Strych U; Ferguson MC; Bottazzi ME; Randall SL; Siegmund SS; Cox SN; Hotez PJ; Lee BY
  • Am J Prev Med 2021[May]; 60 (5): 605-613 PMID33632650show ga
  • INTRODUCTION: During a pandemic, there are many situations in which the first available vaccines may not have as high effectiveness as vaccines that are still under development or vaccines that are not yet ready for distribution, raising the question of whether it is better to go with what is available now or wait. METHODS: In 2020, the team developed a computational model that represents the U.S. population, COVID-19 coronavirus spread, and vaccines with different possible efficacies (to prevent infection or to reduce severe disease) and vaccination timings to estimate the clinical and economic value of vaccination. RESULTS: Except for a limited number of situations, mainly early on in a pandemic and for a vaccine that prevents infection, when an initial vaccine is available, waiting for a vaccine with a higher efficacy results in additional hospitalizations and costs over the course of the pandemic. For example, if a vaccine with a 50% efficacy in preventing infection becomes available when 10% of the population has already been infected, waiting until 40% of the population are infected for a vaccine with 80% efficacy in preventing infection results in 15.6 million additional cases and 1.5 million additional hospitalizations, costing $20.6 billion more in direct medical costs and $12.4 billion more in productivity losses. CONCLUSIONS: This study shows that there are relatively few situations in which it is worth foregoing the first COVID-19 vaccine available in favor of a vaccine that becomes available later on in the pandemic even if the latter vaccine has a substantially higher efficacy.
  • |COVID-19 Vaccines/*administration & dosage[MESH]
  • |COVID-19/epidemiology/*prevention & control[MESH]
  • |Computer Simulation[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]
  • |United States/epidemiology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box